QCI Interpret for Oncology

Going beyond: Molecular evidence for off-label therapy use

June 02, 2021
Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN Digital Insights explains
•Using molecular pathways to expand therapy options
•Identifying evidence-based therapy options for cancer patients for whom there is no on-label therapy
•Providing confidence with expert-curated, oncologist-reviewed treatment strategies

Related videos

QCI Interpret for Oncology

Confidence and trust: Deliver valuable clinical insights with high-quality knowledge

213 views June 02, 2021

Ben Turner, Director of Bioinformatics Enterprise Solutions, QIAGEN Digital...

QCI Interpret for Oncology

Generate oncologist-ready clinical reports from comprehensive panels

219 views June 02, 2021

Ruth Burton, Ph.D., Clinical Application Specialist, QIAGEN Digital Insights...

QCI Interpret for Oncology

Gaining insights with transcriptomic profiling and mechanistic modeling

326 views June 11, 2021

In this webinar, Moritz Schütte, head of next-generation sequencing data...

QCI Interpret for Oncology

QCI Interpret One: Oncology variant interpretation just got more precise

954 views June 12, 2020

Competing to offer a comprehensive genomic profiling service for solid or...